Doug Cole, M.D.

Flagship Pioneering

Dr. Cole is a Managing Partner at life sciences venture firm Flagship Pioneering, which he joined in 2001. Before joining Flagship, Dr. Cole was an Instructor in Neurology at Harvard Medical School and Assistant in Neurology at the Massachusetts General Hospital; Medical Director at Cytotherapeutics; and Program Executive at Vertex Pharmaceuticals. At Flagship, Dr. Cole has co-founded Ensemble Therapeutics, Permeon Biologics, Moderna Therapeutics, Syros Pharmaceuticals, Sigilon Therapeutics, and Foghorn Therapeutics. He has led investments in Agios Pharmaceuticals, Alvine Pharmaceuticals, Avedro, CombinatoRx, Concert Pharmaceuticals, Denali Therapeutics, Editas, Quanterix Corporation, Receptos, Seventh Sense Biosystems, Tetraphase Pharmaceuticals, and Torque. He currently serves on the board of directors of Denali, Editas, Foghorn, Quanterix, Sigilon, TARIS and Torque. Dr. Cole holds an A.B. magna cum laude with high distinction in English from Dartmouth College, and an M.D. from the University of Pennsylvania School of Medicine. He obtained post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at the Massachusetts General Hospital. Dr. Cole is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.